Literature DB >> 3485650

Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids.

B P Lukert, J C Higgins, M M Stoskopf.   

Abstract

Osteocalcin (OC) is a vitamin K-dependent protein which is synthesized by osteoblasts and is present in the circulation. We measured serum OC concentrations in 10 patients receiving corticosteroids (CS) for chronic obstructive pulmonary disease and in 9 hyperthyroid (HT) patients. Mean values ( +/- SE) were as follows: There was a significant correlation between OC and alkaline phosphatase (r = 0.607; P = 0.006) when CS and HT groups were combined. Elevated serum OC concentrations in hyperthyroid patients may reflect increased osteoblastic activity, while decreased levels in corticosteroid-treated patients may reflect decreased osteoblastic activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485650     DOI: 10.1210/jcem-62-5-1056

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Serum osteocalcin concentrations in patients with rheumatoid arthritis.

Authors:  P Pietschmann; K P Machold; W Wolosczuk; J S Smolen
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

2.  Osteocalcin and bone mineral content in rheumatoid arthritis.

Authors:  A Peretz; J P Praet; S Rozenberg; D Bosson; J P Famaey; P Bourdoux
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

3.  Differences in basal and postexercise osteocalcin levels in athletic and nonathletic humans.

Authors:  S Nishiyama; S Tomoeda; T Ohta; A Higuchi; I Matsuda
Journal:  Calcif Tissue Int       Date:  1988-09       Impact factor: 4.333

4.  Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications.

Authors:  P Pietschmann; G Schernthaner; W Woloszczuk
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

5.  A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.

Authors:  M T McDermott; J J Perloff; G S Kidd
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

6.  Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing's syndrome.

Authors:  A Sartorio; A Conti; S Ferrario; E Passini; T Re; B Ambrosi
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

7.  Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis.

Authors:  H Franck; E Keck
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

8.  The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.

Authors:  M Yamamoto; A Markatos; J G Seedor; P Masarachia; M Gentile; G A Rodan; R Balena
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

9.  Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Alexander G Solodovnikov; Liudmila Y Rozhinskaya; Larisa K Dzeranova; Ivan I Dedov
Journal:  Bonekey Rep       Date:  2016-06-15

10.  Increased rat femur osteocalcin mRNA concentrations following in vivo administration of thyroid hormone.

Authors:  D S Ross; R Graichen
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.